J.P. Morgan analyst Anupam Rama has maintained their bullish stance on BBIO stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Anupam Rama has given his Buy rating due to a combination of factors tied to BridgeBio’s clinical and commercial momentum. The company reported highly favorable phase 3 results for infigratinib in achondroplasia, with the trial achieving its main and key secondary efficacy goals and demonstrating height gains that compare well versus an existing approved therapy.
Additional benefits were seen across different age groups, including meaningful improvements in growth metrics and body proportions in younger children, while the safety profile appeared clean with no serious drug-related events or discontinuations. Rama also points to the anticipated regulatory filings for achondroplasia and the strong launch trajectory of Attruby, arguing that together with the advancing late-stage pipeline these drivers should support revenue growth and justify an Overweight stance on BBIO shares.
In another report released today, Goldman Sachs also maintained a Buy rating on the stock with a $112.00 price target.
Based on the recent corporate insider activity of 85 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BBIO in relation to earlier this year.